WO2014174509A1 - Fibrinogen-based tissue adhesive patches - Google Patents
Fibrinogen-based tissue adhesive patches Download PDFInfo
- Publication number
- WO2014174509A1 WO2014174509A1 PCT/IL2014/050347 IL2014050347W WO2014174509A1 WO 2014174509 A1 WO2014174509 A1 WO 2014174509A1 IL 2014050347 W IL2014050347 W IL 2014050347W WO 2014174509 A1 WO2014174509 A1 WO 2014174509A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polymer film
- fibrinogen
- placing
- sealant
- thrombin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/58—Adhesives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/225—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/64—Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C37/00—Component parts, details, accessories or auxiliary operations, not covered by group B29C33/00 or B29C35/00
- B29C37/0025—Applying surface layers, e.g. coatings, decorative layers, printed layers, to articles during shaping, e.g. in-mould printing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C39/00—Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressure; Apparatus therefor
- B29C39/02—Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressure; Apparatus therefor for making articles of definite length, i.e. discrete articles
- B29C39/12—Making multilayered or multicoloured articles
- B29C39/123—Making multilayered articles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/106—Halogens or compounds thereof, e.g. iodine, chlorite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L2300/254—Enzymes, proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2023/00—Use of polyalkenes or derivatives thereof as moulding material
- B29K2023/04—Polymers of ethylene
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2995/00—Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
- B29K2995/0037—Other properties
- B29K2995/0056—Biocompatible, e.g. biopolymers or bioelastomers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
- B29L2031/00—Other particular articles
- B29L2031/753—Medical equipment; Accessories therefor
Definitions
- This invention relates generally to coagulant-containing polymer films that are used as tissue sealants.
- it relates to a polymer film that incorporates fibrinogen and thrombin in which the fibrinogen acts to attach the polymer film to the tissue.
- Wound dressings, tissue coatings, and tissue adhesives are examples of devices that serve to stop or prevent leakage of blood and other bodily fluids. These dressings can serve to seal open wounds, prevent infection, and so on. Many types of wound dressings and tissue adhesives known in the literature incorporate one or more coagulants such as fibrinogen.
- U.S. Pat. No. 5631011 discloses a tissue treatment composition comprising fibrin or fibrinogen and a polymer that is biodegradable and biocompatible. The composition acts as a glue to bind tissue, e.g. a cut and sutured blood vessel.
- U.S. Pat. No. 6699844 discloses a fibrin-containing tissue sealant that also contains a derivative of hyaluronic acid.
- a hemostatic tissue sealant comprising a biocompatible, biodegradable hydrogel tissue sealant comprising crosslinkable groups having incorporated therein an effective amount of a hemostatic agent to stop the flow of blood from tissue in a medically acceptable period of time.
- U.S. Pat. No. 6056970 discloses compositions, produced by known paper-making technology, that comprise hemostatic compounds and bioabsorbable polymers.
- compositions that can release a pharmaceutically effective agent such as a hemostatic agent from a polymeric matrix.
- a pharmaceutically effective agent such as a hemostatic agent
- U.S. Pat. No. 6194005 discloses a method in which a powdered pharmaceutically effective agent is sprayed onto a warm lipid matrix, which thereby coats the agent.
- U.S. Pat. No. 6579537 discloses a method for producing inter alia a fibrinogen composition using a polyalkylene glycol. The basic method comprises producing a solution of fibrinogen and fibronectin and precipitating the fibrinogen and fibronectin by adding a polyalkylene glycol and an amino acid.
- 2012/0121532 discloses a method for preparing a dry and stable hemostatic composition.
- a dry hemostatic agent is mixed with a dry polymeric component in proportions such that on addition of an appropriate diluent (e.g. water), a polymeric matrix (e.g. a hydrogel) into which the hemostatic agent is incorporated.
- an appropriate diluent e.g. water
- a polymeric matrix e.g. a hydrogel
- non-fibrous polymer films or coatings that incorporate a hemostatic agent such as thrombin.
- a hemostatic agent such as thrombin.
- U.S. Pat. Appl. Pub. No. 2007/0059346 discloses a film containing nitroglycerin and possibly other therapeutic agents; the film is made of a water-soluble polymer that can dissolve in the mouth of a patient.
- U.S. Pat. No. 7189410 discloses a layered fibrin sealant bandage comprising a backing layer and a hemostatic component layer containing fibrinogen, the fibrinogen acting to produce a clot when the bandage is applied to a wound.
- a family of patents that includes inter alia U.S. Pat. No. 6054122 discloses fibrin sealant bandages that comprise an occlusive backing, an adhesive layer on the wound-facing surface of the backing, and a layer of dry hemostatic materials (fibrinogen, thrombin, and Ca 2+ and/or Factor XIII as necessary).
- U.S. Pat. Appl. Pub. No. 2006/0155235 discloses a hemostatic compression bandage that bandage comprises a flexible backing element, a powdered hemostatic substance, and a flexible film element. In this bandage, the hemostatic substance remains as a free powder. Immediately prior to use, the flexible film element is peeled away, exposing the powder, which is then placed directly on the wound.
- WO2006/044882 discloses a reinforced absorbable multilayered hemostatic wound dressing that comprises a first absorbable nonwoven fabric comprising aliphatic polyester polymers, copolymers, or blends thereof reinforced by a second absorbable woven or knitted fabric comprising oxidized regenerated cellulose and thrombin and fibrinogen.
- U.S. Pat. Appl. Pub. No. 2011/0288462 discloses a hemostatic wound dressing that comprises a super- absorbent polymer and a hemostatic agent.
- the fibrin sealant component serves the dual role of adhering to the tissue and as a coagulant.
- the backing is used to support the fibrinogen, which must therefore be used in relatively large quantities.
- the invention herein disclosed is designed to meet this long-felt need. It is therefore an object of this invention to disclose a fibrinogen-based tissue adhesive patch, comprising a backing made from a film made of a biocompatible polymer and a fibrinogen sealant. It is within the essence of the invention wherein said fibrinogen sealant is incorporated into said biocompatible polymer backing.
- said fibrinogen sealant comprises fibrinogen, thrombin, and CaCl 2 .
- said fibrinogen sealant comprises fibrinogen but does not comprise thrombin.
- said fibrinogen sealant consists essentially of fibrinogen, thrombin, and CaCl 2 .
- said fibrinogen sealant consists essentially of fibrinogen.
- tissue adhesive patch does not include any mesh or woven component.
- tissue adhesive patch wherein said tissue adhesive patch does not comprise any hemostatic agent in the form of a free powder.
- tissue adhesive patch as defined in any of the above, wherein said biocompatible polymer is non-permeable.
- biocompatible polymer is selected from the group consisting of polyethylene glycol - polycaprolactone copolymers; polyethylene glycol - DL- lactide copolymers; and polyethylene glycol - polycaprolactone - DL-lactide copolymers.
- tissue adhesive patch as defined in any of the above, wherein said backing has a thickness of about 200 ⁇ .
- tissue adhesive patch as defined in any of the above, wherein said patch comprises between 0.5 mg and 8 mg of fibrinogen and between 20 IU and 1000 IU of thrombin per square centimeter of film.
- said fibrinogen sealant comprises fibrinogen, thrombin, and CaCl 2 in a ratio of 425 : 5 : 11 by weght.
- said fibrinogen sealant additionally comprises at least one additive.
- said additive is selected from the group consisting of additives for extending the adhesion half-life of said film, pharmaceutically active agents, and analgesics.
- said additive is a plasmin inhibitor for extending the adhesion half-life of said film.
- said additive is a pharmaceutically active agent for targeted or controlled release.
- said step of placing a fibrinogen sealant on at least one surface of said polymer film comprises placing a fibrinogen sealant comprising fibrinogen, thrombin, and CaCl 2 on at least one surface of said polymer film.
- said step of placing a fibrinogen sealant on at least one surface of said polymer film comprises placing a fibrinogen sealant comprising fibrinogen but not comprising thrombin on at least one surface of said polymer film. In some embodiments of the method, said step of placing a fibrinogen sealant on at least one surface of said polymer film comprises placing a fibrinogen sealant consisting essentially of fibrinogen, thrombin, and CaCl 2 on at least one surface of said polymer film. In some embodiments of the method, said step of placing a fibrinogen sealant on at least one surface of said polymer film comprises placing a fibrinogen sealant consisting essentially of fibrinogen on at least one surface of said polymer film.
- biocompatible polymer is non-permeable.
- biocompatible polymer is selected from the group consisting of polyethylene glycol - polycaprolactone copolymers; polyethylene glycol - DL-lactide copolymers; and polyethylene glycol - polycaprolactone - DL-lactide copolymers.
- said step of casting a polymer film comprises preparing a solution of a dry polymer in an organic solvent and evaporating said organic solvent.
- said step of preparing a solution of dry polymer in organic solvent comprises preparing a 3 - 5% (w/v) solution.
- said step of preparing a solution of dry polymer in organic solvent comprises preparing a solution of dry polymer in an organic solvent selected from the group consisting of THF, chloroform, dioxane, acetone, l-methyl-2-pyrrolidinone, DMF, and DMA.
- said step of preparing a solution of dry polymer in organic solvent comprises preparing a solution of dry polymer in THF. In some embodiments of the invention, it further comprises covering said solution during at least part of the time that said step of evaporating said organic solvent is taking place.
- step of casting a polymer film comprises casting said polymer film on a smooth flat surface.
- step of placing said polymer film on a smooth flat surface comprises placing said polymer film on a surface made of a material selected from the group consisting of glass, silicone, and polytetrafluoroethylene.
- said step of placing said polymer film on a smooth flat surface comprises placing said polymer film on a glass surface.
- the method further comprises a step of removing said polymer film from said smooth flat surface following said step of pressing said polymer film.
- it further comprises a step of placing said polymer film in a freezer following said step of pressing said polymer and prior to said step of removing said polymer film from said smooth flat surface.
- said step of placing said polymer film in a freezer comprises placing said polymer film in a freezer at a temperature of between -25 °C and -15 °C.
- step of softening said polymer film comprises heating said polymer film until said polymer film softens.
- step of heating said polymer film until said polymer film softens comprises heating said polymer film to a temperature of between 55 °C and 60 °C.
- step of pressing said polymer film is followed by a step of cooling said polymer film sufficiently slowly that the film returns substantially to its original morphology.
- step of softening said polymer film comprises softening said polymer film by using residual solvent.
- said step of placing a fibrinogen sealant comprising fibrinogen, thrombin, CaCl 2 and at least one additive on at least one surface of said polymer film comprises placing a fibrinogen sealant comprising fibrinogen, thrombin, CaCl 2 and at least one additive selected from the group consisting of additives for extending the adhesion half-life of said polymer film, pharmaceutically active agents, and analgesics on at least one surface of said polymer film.
- said step of placing a fibrinogen sealant comprising fibrinogen, thrombin, CaCl 2 and at least one additive on at least one surface of said polymer film comprises placing a fibrinogen sealant comprising fibrinogen, thrombin, CaCl 2 and a plasmin inhibitor on at least one surface of said polymer film.
- said step of placing a fibrinogen sealant comprising fibrinogen, thrombin, CaCl 2 and at least one additive on at least one surface of said polymer film comprises placing a fibrinogen sealant comprising fibrinogen, thrombin, CaCl 2 and at least one pharmaceutically active agent for targeted or sustained release on at least one surface of said polymer film.
- said step of placing a fibrinogen sealant comprising fibrinogen, thrombin, and CaCl 2 on at least one surface of said polymer film comprises placing said powder on said at least one surface by a method selected from the group consisting of sprinkling, spreading, spraying, and spraying a suspension of said powder in an organic solvent.
- step of pressing said polymer film comprises pressing said polymer film according to a programmed compression procedure.
- said step of pressing said polymer film according to a programmed compression procedure comprises pressing said polymer film with a force that continuously increases to a maximum of about 50 N.
- tissue adhesive patch as defined in any of the above, produced by a method as defined in any of the above.
- said body part is selected from the group consisting of arteries and organs.
- said step of applying a tissue adhesive patch comprises manually pressing said patch on the surface of said body part.
- said body part is selected from the group consisting of arteries and organs.
- said step of applying a tissue adhesive patch comprises manually pressing said patch on the surface of said body part.
- tissue adhesive patch as defined in any of the above in the treatment of a leak of fluid into or out of a body part.
- FIG. 1 presents a graph showing the tensile modulus of wet and dry films made from a polyethylene glycol - polycaprolactone copolymer (PECA) as function of the ratio of ethylene oxide (EO) to caprolactone (CL) units in the polymer;
- PECA polyethylene glycol - polycaprolactone copolymer
- FIG. 2 presents graphs showing the tensile modulus of wet polyethylene - caprolactone - lactide (PECALA) films of varying compositions in comparison to a PECA film with an EO/CL ratio of 2.0;
- PECALA wet polyethylene - caprolactone - lactide
- FIG. 3 shows DSC traces for wet and dry PECA films of different ethylene oxide / caprolactone ratios and for wet PECALA films of varying compositions
- FIG. 4 presents results of measurements of water uptake by dry PECA films of different ethylene oxide / caprolactone ratios and for dry PECALA films of varying compositions;
- FIG. 5 shows a photograph of a fibrinogen-based tissue adhesive film according to one embodiment of the present invention
- FIG. 6 shows a photograph of fibrinogen-based tissue adhesive film according to one embodiment of the present invention attached to a piece of raw meat after 60 minutes of washing under running water;
- FIG. 7 shows a photograph of a typical measurement of the force required to detach the adhesive film of the present invention from raw meat used as a substrate;
- FIG. 8 shows photographs illustrating an in-vivo biodegradability assessment and adhesion/detachment force measurement;
- FIG. 9 shows the use of an adhesive patch of the present invention to seal a 3 mm hole in a rat caecum.
- FIG. 10 shows the use of an adhesive patch of the present invention to seal a 5 mm puncture hole in a rat liver.
- PEG polyethylene glycol and polyethylene oxide, respectively, and are used interchangeably.
- PECA refers to a PEG - polycaprolactone (PCL) block copolymer.
- PCL polycaprolactone
- PELA refers to a block copolymer of PEG with lactide, the cyclic diester of lactic acid.
- PECALA refers to a triblock PEG - PCL - lactide triblock copolymer.
- PECALA hydrophilic
- PCL and lactide hydrophobic
- the backing of the fibrinogen-based tissue adhesive of the present invention comprises a film made from a biocompatible polymer into the surface of which a fibrin-based sealant is incorporated.
- the biocompatible polymer film is made from a non-permeable material.
- the biocompatible polymer film is made from PECA, PELA, or PECALA.
- the sealant in its most basic formulation, consists essentially of fibrinogen, thrombin, and CaCl 2 .
- the sealant comprises fibrinogen, thrombin, and CaCl 2 , and may contain one or more additional components.
- additional components include plasmin inhibitors, which serve to extend the adhesion half- life; pharmaceutically active agents; and analgesics.
- the sealant contains fibrinogen, thrombin, and CaCl 2 in a ratio of 425 : 5 : 11 by weight. This ratio corresponds to -200 mg pure fibrinogen, -250 IU thrombin, and 11 mg CaCl 2 per 441 mg of the mixture.
- no CaCl 2 is added to the adhesive, the amount of CaCl 2 present in the thrombin as received from commercial suppliers being sufficient to act as a cofactor for the enzymatic activity of the thrombin.
- the sealant is a microparticulate powder, and the amount of sealant incorporated into the film is sufficient to provide a concentration of 0.5 - 8 mg of fibrin and 20 - 10000 IU of thrombin per square centimeter of film. This concentration corresponds to about 3 - 6 mg of the 425 : 5 : 11 mixture described above.
- the concentration of fibrinogen in the adhesive is between 0.5 and 6 mg per square centimeter of film.
- the adhesive provides about 4 mg fibrinogen and about 2 - 5 IU of thrombin per square centimeter of film. In the most preferred embodiments, the concentration of fibrinogen in the adhesive is less than 2 mg per square centimeter of film.
- the patch is provided as a two-component system.
- the sealant does not contain any thrombin.
- the sealant consists essentially of fibrinogen; in others, the sealant comprises fibrinogen, but may contain other components, non-limiting examples of which include plasmin inhibitors, which serve to extend the adhesion half-life; pharmaceutically active agents; and analgesics.
- thrombin is provided separately; as a non-limiting example, it can be provided in a solution.
- the thrombin component is applied to the affected body part, e.g.
- the patch containing the fibrinogen- based sealant is then applied to the affected body part.
- the fibrinogen component of the sealant and the thrombin applied to the affected body part then react to form fibrin, which binds the patch to the affected body part.
- tissue adhesive of the present invention do not include a mesh or woven component; the polymer film, not the fibrinogen sealant, acts to seal the tissue, while the fibrinogen acts to attach the polymer film to the tissue.
- preferred embodiments of the present invention comprise woven or non-woven fabrics or materials made by techniques known in paper-making technology.
- the present invention discloses in its preferred embodiments a tissue adhesive that comprises a single layer of polymer film into which fibrinogen and thrombin are incorporated, in contrast to multilayer hemostatic dressings known in the art (although embodiments in which additional layers are added for ease of handling or storage are not excluded from the scope of the present invention).
- the fibrinogen sealant component is physically incorporated into the polymer film to form a single integrated unit (as described below, in preferred embodiments, it is pressed into the surface of the film), in contrast to those hemostatic patches and dressings known in the art in which the coagulant is present as a free powder.
- tissue adhesive of the present invention enables the tissue adhesive of the present invention to be used in a variety of unique applications.
- Non-limiting examples of applications in which the present invention can be used include covering traumatic and chronic wounds, stopping of arterial bleeding, stopping organ tissue bleeding, and sealing of other body fluids, for example, in treatment of bile anastomosis, cerebrospinal fluid and dura leaks, etc.
- Table 1 summarizes some of the properties of PEC A copolymers, as determined by GPC and 1 H-NMR, as a function of the EO/CL ratio. The molecular weights reported in the table are true molecular weights and not polystyrene equivalents. TABLE 1
- PECA One property of PECA that makes it less preferred for some applications as a material for the backing of a hemostatic patch is its relatively slow rate of biodegradation; e.g., an in vitro test of a number of PECA films of varying compositions showed little degradation even after three months. Therefore, in some preferred embodiments of the invention in which rapid biodegradation is desired, PEC ALA films, which incorporate DL-lactide units into the CL segments, and hence biodegrade much more rapidly than PECA films, are used. Table 2 summarizes the properties, as determined by GPC and 1H-NMR spectroscopy, of PECALA films of various compositions.
- FIG. 1 shows the tensile moduli of dry (FIG. 1A) and wet (FIG. IB) PECA films as a function of the EO/CL ratio.
- the differences in the behavior of the dry and wet polymer films are primarily due to the ratio of the amount of hydrophilic PEG to hydrophobic PCL in the polymer films. Note that for the dry polymer films, the tensile modulus rises from -60 MPa for PECA2.0 to -160 MPa for PECA5.2, but appears to plateau at higher EO/CL ratios. In contrast, the tensile modulus of the wet polymer decreases with increasing EO/CL.
- FIG. 2A shows graphically the tensile moduli of several wet PECALA films.
- the tensile modulus of a wet PECA2.0 film is shown for comparison.
- FIGs. 2B and 2C show the tensile moduli and stress at break, respectively, for two different PECALA films in comparison to PECA2.8. These graphs show that PECALA's physical properties are similar to those of PECA.
- FIG. 3 presents DSC traces showing the thermal transitions of polymer films of various compositions.
- FIG. 3A shows a trace for FECA2.0, the melt of which (trace 301 in the figure) shows evidence for two components, and in which the cooling of the melt (trace 302 in the figure) shows two distinct recrystallizations. The larger peak belongs to the caprolactone segment.
- FIG. 3B shows DSC traces for dry PECA films of various EO/CL ratios
- FIG. 3C shows DSC traces for wet PECA films of various EO/CL ratios.
- FIG. 3D shows DSC traces for PECALA films of various compositions, with a DSC trace of a PECA2.0 film shown for comparison.
- These DSC traces support the conjecture that the lactide unit disrupts the crystallinity of the caprolactone segments.
- the traces show that for PECALA2.2 DL 2.81 and 3.55 films, the incorporation of lactide units destroys the polymer's crystallinity.
- FIG. 4A shows the water uptake (w/w, measured gravimetrically) after 5 and 60 minutes of a number of PECA films of various EO/CL ratios. The results show that water rapidly saturates the material.
- FIG. 4B shows the water uptake (w/w, measured gravimetrically) for two PECALA compositions in comparison to two PECA compositions. As with PECA, PECALA saturates rapidly.
- a preferred method of preparing the fibrinogen-based tissue adhesive of the present invention is now disclosed.
- a non-permeable biocompatible polymer film is cast; in preferred embodiments, the film is made from PECA, PELA, or PECALA.
- the film can be prepared by any method known in the art.
- a solution typically 3 - 5%
- the solvent is THF, but any sufficiently volatile organic solvent may be used instead.
- suitable solvents include chloroform, dioxane, acetone, l-methyl-2-pyrrolidinone, DMF, and DMA.
- the solution is covered, e.g. by perforated aluminum foil, so that the solvent does not evaporate too quickly and to prevent dust contamination, which can lead to surface defects.
- the film can be of any thickness suitable for the desired final application; in typical embodiments, the film has a thickness of approximately 200 ⁇ .
- the polymer film is then placed on a supporting horizontal surface made of a smooth flat material from which it will be possible to remove the film without damaging it; non-limiting examples of such surfaces include glass and sheets made from inert polymers such as silicone or polytetrafluoroethylene.
- the film is then softened, in preferred embodiments by heating (typically to about 55 - 60°C) or by residual solvent.
- the smooth surface is a flexible polymer sheet
- a sheet of rigid material such as glass is placed between the polymer sheet and the heating element for ease of handling.
- the softened film is then covered by a homogeneous fibrin sealant mixture.
- the mixture typically comprises fibrinogen, thrombin, CaCl 2 , and optionally additives, as described above.
- thrombin is not incorporated directly into the polymer, and the fibrin sealant comprises fibrinogen and optionally additives.
- additives that can be incorporated into the mixture include additives for extending the adhesion half-life such as plasmin inhibitors, pharmaceutically active agents for targeted or sustained release, and analgesics.
- the fibrin sealant mixture is then added as a powder to the softened polymer film.
- the powder may be added by any method known in the art. Non-limiting methods include sprinkling over the polymer film, spraying, spraying a suspension of the powder in a volatile organic solvent onto the film, or simply spreading the powder over the surface of the film. In preferred embodiments, the mixture is added in an amount sufficient to provide 0.5 - 8 mg of fibrinogen and 20 - 1000 IU of thrombin/cm of film.
- thrombin is not included in the fibrin sealant, but is applied separately to the affected body part, in preferred embodiments, in concentrations sufficient to provide 20 - 1000 IU / cm of film applied to the body part.
- the polymer film is then covered with a smooth material having a flat surface; suitable materials described above for the supporting horizontal surface are also suitable for use as the covering surface.
- the covering surface is a flexible polymer
- the flexible polymer is covered with a rigid smooth material such as a glass plate in order that when the softened film is pressed (see the following paragraph), the pressure on the film is homogeneously applied.
- the fibrin sealant mixture is then pressed into the surface of the softened polymer film.
- the pressing may be done by any method known in the art.
- a programmed compression procedure is used in which the compressive force increases during the compression up to a maximum of 50 N.
- the actual compressive force can be adjusted according to the thickness and composition of the specific film being used; the force need only be sufficient to incorporate the powder into the surface of the softened polymer film.
- the film (still between the two smooth flat surfaces) is removed from the heating apparatus and allowed to cool to room temperature at a rate sufficiently slow such that it returns essentially to its original morphology, thus substantially retaining the mechanical, physical, and chemical properties of the film as originally formed.
- room temperature Once the film has returned to room temperature, it may optionally be placed in a freezer (typical freezer temperatures are -15 to -25 °C) for -15 minutes in order to make it easier to remove the film from the surfaces between which it sits.
- freezing is generally not necessary, since the film can be peeled from the backing surfaces without risk of damage.
- a 4.3% w/v solution of dry PECALA in THF was prepared and poured into a glass Petri dish. The dish was covered with perforated aluminum foil and left overnight at room temperature in a fume hood. The resulting film had a thickness of approximately 200 ⁇ .
- An adhesive tissue patch according to one embodiment of the present invention was prepared and attached to a piece of raw meat and then washed extensively under a stream of water. As shown in FIG. 6, the patch remained firmly attached even after 60 minutes of washing.
- IP intraperitoneal
- FIG. 8A shows the implantation site for implantation of adhesive patch 100 on the liver at day 0, and FIG. 8B shows the implantation site for implantation of adhesive patch 100 on the liver on day 14 following the implantation.
- FIGs. 8C and 8D show the implantation site for implantation on the caecum at days 0 and 14, respectively.
- the adhesive patches remained visibly attached to the implantation site 14 days after implantation.
- a patch was prepared as described in Example 1 above, except that instead of a sealant mixture containing fibrinogen, thrombin, and CaCl 2 , only powdered fibrinogen was sprinkled onto the surface of the softened polymer film. A solution of thrombin was sprayed onto a piece of raw meat and the patch pressed onto the meat for 2 minutes. The adherence of the patch prepared in this manner was identical to that of that of a patch applied as described in Example 3.
- a 6 mm hole was made in the left lobe of the liver of the test animals using a biopsy punch, resulting in severe bleeding.
- the hole was then covered with a 1.4 cm diameter patch of the present invention made from PECALA and containing 2 mg/cm fibrin sealant.
- the device adhered well to the tissue, sealing the hole and stopping the bleeding instantly.
- FIG. 10 shows the liver of an experimental animal after the puncture and application of the patch (the puncture hole can be seen beneath the transparent patch). After hemostasis was evident, the liver was returned to the abdominal cavity. The animals were kept alive for two weeks following the treatment and then sacrificed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2910017A CA2910017C (en) | 2013-04-22 | 2014-04-10 | Fibrinogen-based tissue adhesive patches |
CN201480035725.2A CN105555299B (en) | 2013-04-22 | 2014-04-10 | Fibrinogen-based tissue adhesive patch |
AU2014258995A AU2014258995B2 (en) | 2013-04-22 | 2014-04-10 | Fibrinogen-based tissue adhesive patches |
ES14788015T ES2714449T3 (en) | 2013-04-22 | 2014-04-10 | Fibrinogen-based tissue adhesive patches |
JP2016509603A JP6446031B2 (en) | 2013-04-22 | 2014-04-10 | Fibrinogen-based tissue adhesive patch |
EP14788015.7A EP2988771B1 (en) | 2013-04-22 | 2014-04-10 | Fibrinogen-based tissue adhesive patches |
US14/785,857 US20160067371A1 (en) | 2013-04-22 | 2014-04-10 | Fibrinogen-based tissue adhesive patches |
KR1020157033369A KR102244014B1 (en) | 2013-04-22 | 2014-04-10 | Fibrinogen-based tissure adhesive patches |
IL242244A IL242244B (en) | 2013-04-22 | 2015-10-22 | Fibrinogen-based tissue adhesive patches |
US16/041,903 US11071805B2 (en) | 2013-04-22 | 2018-07-23 | Fibrinogen-based tissue adhesive patches |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361814355P | 2013-04-22 | 2013-04-22 | |
US61/814,355 | 2013-04-22 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/785,857 A-371-Of-International US20160067371A1 (en) | 2013-04-22 | 2014-04-10 | Fibrinogen-based tissue adhesive patches |
US16/041,903 Continuation-In-Part US11071805B2 (en) | 2013-04-22 | 2018-07-23 | Fibrinogen-based tissue adhesive patches |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014174509A1 true WO2014174509A1 (en) | 2014-10-30 |
Family
ID=51791147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2014/050347 WO2014174509A1 (en) | 2013-04-22 | 2014-04-10 | Fibrinogen-based tissue adhesive patches |
Country Status (10)
Country | Link |
---|---|
US (1) | US20160067371A1 (en) |
EP (1) | EP2988771B1 (en) |
JP (1) | JP6446031B2 (en) |
KR (1) | KR102244014B1 (en) |
CN (1) | CN105555299B (en) |
AU (1) | AU2014258995B2 (en) |
CA (1) | CA2910017C (en) |
ES (1) | ES2714449T3 (en) |
IL (1) | IL242244B (en) |
WO (1) | WO2014174509A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017068572A1 (en) * | 2015-10-19 | 2017-04-27 | Sealantium Medical Ltd | Improved fibrinogen-based tissue adhesive patch |
WO2019180713A1 (en) | 2018-03-22 | 2019-09-26 | Sealantium Medical Ltd | Method for determining the adhesive force of a hemostatic tissue sealant patch |
US11071805B2 (en) | 2013-04-22 | 2021-07-27 | Sealantium Medical Ltd. | Fibrinogen-based tissue adhesive patches |
US11471556B2 (en) | 2015-10-19 | 2022-10-18 | Sealantium Medical Ltd. | Fibrinogen-based tissue adhesive patch |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107754005B (en) * | 2016-08-15 | 2021-06-15 | 广州倍绣生物技术有限公司 | Hemostatic compositions and methods of making same |
CN108236738A (en) * | 2016-12-26 | 2018-07-03 | 苏州东泉生物科技有限公司 | A kind of bion composite material oesophagus sticking patch with radio therapy sensitization |
CN108236741A (en) * | 2016-12-26 | 2018-07-03 | 苏州东泉生物科技有限公司 | A kind of bion composite material oesophagus sticking patch |
CN108236740A (en) * | 2016-12-26 | 2018-07-03 | 苏州东泉生物科技有限公司 | A kind of composite material oesophagus sticking patch |
CN111670056B (en) * | 2018-01-31 | 2023-01-10 | 罗基医疗保健公司 | Bio-ink composition for dermal regeneration sheet, method for producing customized dermal regeneration sheet using same, and customized dermal regeneration sheet produced by said production method |
CN110368516A (en) * | 2019-07-06 | 2019-10-25 | 袁斯曼 | A kind of preparation method of high bonding degradable adhesive fibrin |
CN111450323A (en) * | 2020-04-29 | 2020-07-28 | 天津百和至远医疗技术有限公司 | Instant adhesive tissue patch and preparation method thereof |
CN116437945A (en) * | 2020-08-31 | 2023-07-14 | 维特鲁威医疗器械有限公司 | Storage stable film comprising fibrin and/or fibrinogen |
CN112354002A (en) * | 2020-11-12 | 2021-02-12 | 广东深蓝生物科技有限公司 | Hemostatic sealant and preparation method thereof |
CN113733532B (en) * | 2021-08-25 | 2022-10-11 | 中山大学 | Flexible polyester patch and preparation method and application thereof |
WO2023076882A1 (en) * | 2021-10-28 | 2023-05-04 | University Of Florida Research Foundation, Incorporated | Polymeric micelle nanoparticles for on-demand cellular packaging of extracellular vesicles |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008019128A2 (en) * | 2006-08-04 | 2008-02-14 | Stb Lifesaving Technologies, Inc. | Solid dressing for treating wounded tissue |
US20110071498A1 (en) * | 2009-09-18 | 2011-03-24 | Dorna Hakimimehr | Free-standing biodegradable patch |
US20120070485A1 (en) * | 2009-05-26 | 2012-03-22 | Giorgio Soldani | method for producing a device applicable to biological tissues, particularly a patch for treating damaged tissues, and a device obtained by said method |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4946898B1 (en) * | 1971-03-29 | 1974-12-12 | ||
JPS5980253A (en) * | 1982-10-28 | 1984-05-09 | ユニチカ株式会社 | Material for treating wound part |
SE9101853D0 (en) * | 1991-06-17 | 1991-06-17 | Jonas Wadstroem | IMPROVED TISSUE ASHESIVE |
WO1996040174A1 (en) | 1995-06-07 | 1996-12-19 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US6503527B1 (en) * | 1997-11-17 | 2003-01-07 | Haemacure Corporation | Fibrin sealants or adhesives comprising a hyaluronic acid derivative material |
US6056970A (en) * | 1998-05-07 | 2000-05-02 | Genzyme Corporation | Compositions comprising hemostatic compounds and bioabsorbable polymers |
AU7084300A (en) * | 1999-08-27 | 2001-03-26 | Cohesion Technologies, Inc. | Compositions that form interpenetrating polymer networks for use as high strength medical sealants |
US8070810B2 (en) * | 2006-01-12 | 2011-12-06 | Histogenics Corporation | Method for repair and reconstruction of ruptured ligaments or tendons and for treatment of ligament and tendon injuries |
EP2556842A1 (en) * | 2011-08-11 | 2013-02-13 | Bioftalmik, S.L. | Composition in the form of film comprising fibrinogen and a fibrinogen activator and the applications thereof |
CN103611195B (en) * | 2013-11-21 | 2015-04-22 | 无锡中科光远生物材料有限公司 | Self-adhesion hemostasis anti-adhesion corpus fibrosum |
-
2014
- 2014-04-10 CN CN201480035725.2A patent/CN105555299B/en active Active
- 2014-04-10 KR KR1020157033369A patent/KR102244014B1/en active IP Right Grant
- 2014-04-10 ES ES14788015T patent/ES2714449T3/en active Active
- 2014-04-10 JP JP2016509603A patent/JP6446031B2/en active Active
- 2014-04-10 EP EP14788015.7A patent/EP2988771B1/en active Active
- 2014-04-10 AU AU2014258995A patent/AU2014258995B2/en active Active
- 2014-04-10 CA CA2910017A patent/CA2910017C/en active Active
- 2014-04-10 WO PCT/IL2014/050347 patent/WO2014174509A1/en active Application Filing
- 2014-04-10 US US14/785,857 patent/US20160067371A1/en not_active Abandoned
-
2015
- 2015-10-22 IL IL242244A patent/IL242244B/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008019128A2 (en) * | 2006-08-04 | 2008-02-14 | Stb Lifesaving Technologies, Inc. | Solid dressing for treating wounded tissue |
US20120070485A1 (en) * | 2009-05-26 | 2012-03-22 | Giorgio Soldani | method for producing a device applicable to biological tissues, particularly a patch for treating damaged tissues, and a device obtained by said method |
US20110071498A1 (en) * | 2009-09-18 | 2011-03-24 | Dorna Hakimimehr | Free-standing biodegradable patch |
Non-Patent Citations (1)
Title |
---|
See also references of EP2988771A4 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11071805B2 (en) | 2013-04-22 | 2021-07-27 | Sealantium Medical Ltd. | Fibrinogen-based tissue adhesive patches |
WO2017068572A1 (en) * | 2015-10-19 | 2017-04-27 | Sealantium Medical Ltd | Improved fibrinogen-based tissue adhesive patch |
KR20180099636A (en) * | 2015-10-19 | 2018-09-05 | 씨랜티움 메디컬 리미티드 | Improved fibronogen-based tissue adhesion patches |
CN108697829A (en) * | 2015-10-19 | 2018-10-23 | 西兰丁姆医疗公司 | The improved tissue adhesion patch based on fibrinogen |
US11471556B2 (en) | 2015-10-19 | 2022-10-18 | Sealantium Medical Ltd. | Fibrinogen-based tissue adhesive patch |
US11771799B2 (en) | 2015-10-19 | 2023-10-03 | Sealantium Medical Ltd | Method for preparation of tissue adhesive patches |
KR102650472B1 (en) | 2015-10-19 | 2024-03-21 | 씨랜티움 메디컬 리미티드 | Improved fibronogen-based tissue adhesive patch |
WO2019180713A1 (en) | 2018-03-22 | 2019-09-26 | Sealantium Medical Ltd | Method for determining the adhesive force of a hemostatic tissue sealant patch |
GB2586544A (en) * | 2018-03-22 | 2021-02-24 | Sealantium Medical Ltd | Method for determining the adhesive force of a hemostatic tissue sealant patch |
GB2586544B (en) * | 2018-03-22 | 2022-05-04 | Sealantium Medical Ltd | Method for determining the adhesive force of a hemostatic tissue sealant patch |
US11662299B2 (en) | 2018-03-22 | 2023-05-30 | Sealantium Medical Ltd | Method for determining the adhesive force of a hemostatic tissue sealant patch |
Also Published As
Publication number | Publication date |
---|---|
EP2988771A1 (en) | 2016-03-02 |
ES2714449T3 (en) | 2019-05-28 |
KR20160004328A (en) | 2016-01-12 |
EP2988771A4 (en) | 2016-12-21 |
AU2014258995A1 (en) | 2015-11-12 |
KR102244014B1 (en) | 2021-04-23 |
CN105555299A (en) | 2016-05-04 |
IL242244B (en) | 2020-04-30 |
JP2016517738A (en) | 2016-06-20 |
CA2910017A1 (en) | 2014-10-30 |
CN105555299B (en) | 2023-03-28 |
JP6446031B2 (en) | 2018-12-26 |
US20160067371A1 (en) | 2016-03-10 |
CA2910017C (en) | 2022-07-05 |
AU2014258995B2 (en) | 2019-05-23 |
EP2988771B1 (en) | 2018-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2910017C (en) | Fibrinogen-based tissue adhesive patches | |
ES2573699T3 (en) | Composite layered hemostasis device | |
MXPA06007345A (en) | Wound d/ressing and method for controlling severe, life-threatening bleeding. | |
CN107754005B (en) | Hemostatic compositions and methods of making same | |
TW201141546A (en) | Hemostatic sponge | |
CN102665773A (en) | Oxidized regenerated cellulose adhesive tape | |
US8846849B2 (en) | Tissue sealants from plasma derived proteins | |
CA2862545C (en) | Biodegradable non-woven material for medical purposes | |
US10905792B2 (en) | Fibrinogen-based tissue adhesive patch | |
US11771799B2 (en) | Method for preparation of tissue adhesive patches | |
US11071805B2 (en) | Fibrinogen-based tissue adhesive patches | |
CA3008674C (en) | Improved fibrinogen-based tissue adhesive patch | |
JP2018531116A6 (en) | Improved tissue adhesive patch based on fibrinogen | |
Esser | Adhesive polymer films for the prevention of postsurgical adhesions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480035725.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14788015 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2910017 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14785857 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2016509603 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 242244 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2014258995 Country of ref document: AU Date of ref document: 20140410 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014788015 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20157033369 Country of ref document: KR Kind code of ref document: A |